Thu, 02nd Dec 2021 07:09
Dec 2 (Reuters) - GlaxoSmithKline on Thursday said
that a pre-clinical analysis of the antibody-based COVID-19
therapy it is developing with U.S. partner Vir has
indicated that the drug also works against the new Omicron
variant.
Further tests will be carried out on the sotrovimab therapy
to firm up the results, GSK said in a statement.
(Reporting by Ludwig Burger
Editing by David Goodman
)
(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in ...
(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.
(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.
(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.
(Alliance News) - Stocks in London are called to open lower, as investors wait for an inflation reading from the eurozone later this morning.
Glaxosmithkline (GSK)